Proviron hair loss cytidine nucleoside analogue, in which small doses selectively inhibits DNA methyltransferase, which leads to a promoter hypomethylation suppressor genes, their reactivation, induction of cell differentiation or aging of cells and their subsequent programmed death.
Population pharmacokinetic parameters of proviron hair loss have been obtained in the course of the three studies that used 5-day dosing regimen. At the five-day dosing regimen of proviron hair loss pharmacokinetic parameters were evaluated on the fifth day of the first treatment cycle. The total dose per cycle of treatment was 100 mg / m 2 . At the three-day dosing regimen pharmacokinetic parameters of proviron hair loss were assessed every day in the first cycle of treatment, after the first dose.
The total dose per cycle of treatment was 135 mg / m 2 . The pharmacokinetics of proviron hair loss after intravenous infusion duration of 1 hour (5 day regimen) or. 3 hours. (3-day regimen) describes a two-compartment linear model, which is characterized by rapid clearance of the drug from the central chamber and the relatively slow distribution of the peripheral chamber.
Special patient population proviron hair loss exhibits linear pharmacokinetics after intravenous infusion of the equilibrium concentration is reached within 0.5 hour. Simulations have shown that the pharmacokinetic parameters are independent of time (i.e., did not change from cycle to cycle), also under these dosing regimens was observed cumulation. proviron hair loss to a small extent (<1%) bound to plasma proteins. Vd ss proviron hair loss in patients with cancer is an indicator of drug distribution in the peripheral tissues. Revealed no evidence of pharmacokinetic parameters depending on the age, the clearance of creatinine, total bilirubin or stage of disease.Metabolism : proviron hair loss in cells subjected to sequential phosphorylation phosphokinase to the corresponding triphosphate, which is incorporated by DNA polymerase in the DNA. In view of the metabolism of the data obtained in vitro , the results of the mass balance studies demonstrate that the cytochrome P450 involved in the metabolism is not proviron hair loss. proviron hair loss main pathway is likely associated with cytidine deamination in the liver, kidney, intestinal epithelium, and blood. The results of the mass balance study in humans showed that unchanged proviron hair loss in plasma is about 2.4%. proviron hair loss major circulating metabolites are considered pharmacologically inactive. The presence of these metabolites in the urine together with the high and low total clearance excretion of unchanged substance in the urine (~ 4% of the administered dose) indicates significant substance metabolism in vivo . Moreover, the data obtained in vitro suggest that proviron hair loss is a poor substrate for P-glycoprotein (P-gp). Derivation : Middle substance clearance from plasma after intravenous administration to cancer patients is> 200 l / h with moderate individual scatter (Coefficient of Variation (HF) approximately 50%). In unmodified form, apparently only a small part is displayed introduced proviron hair loss. Results Mass balance studies with 14C-radioactive proviron hair loss in cancer patients showed that 90% of the administered dose proviron hair loss (4% unchanged drug) excreted in urine.
pharmacokinetics of proviron hair loss in patients with impaired renal and hepatic function in special studies have not been studied, research based pharmacokinetics of gender, age or race of the patient was carried out. Elderly patients Population pharmacokinetic analysis showed that the pharmacokinetics of proviron hair loss does not depend on age (studied range from 40 to 87 years, mean 70 years). Gender Population pharmacokinetic analysis of proviron hair loss did not reveal any clinically significant differences between men and women. Race Most of the patients participating in the study were Caucasians. However, the group pharmacokinetic analysis indicated that the race did not have a visible effect on the pharmacokinetics of proviron hair loss. Hepatic impairment Pharmacokinetic analysis of proviron hair loss in patients with hepatic insufficiency was not conducted separately. The results of mass-balance studies in humans and experiments in vitro, , mentioned above, indicate that CYP450 isoenzymes are unlikely to participate in the metabolism of proviron hair loss. Moreover, the limited data obtained in the population pharmacokinetic analysis, indicate the absence of valid pharmacokinetic parameters depending on the level of total bilirubin, despite the wide range of bilirubin. Consequently, it is unlikely that the removal of the proviron hair loss will be changed in patients with hepatic insufficiency. Renal insufficiency Pharmacokinetic analysis of proviron hair loss in patients with renal insufficiency was not conducted separately. Population pharmacokinetic analysis of the limited available data on proviron hair loss does not indicate a reliable dependence on the pharmacokinetic parameters of creatinine clearance – indicator of kidney function. Consequently, it is unlikely that the removal of the proviron hair loss will be changed in patients with renal insufficiency. steroiden kaufen
anabolika steroide kaufen
anabolika steroide kaufen